Axillary surgery in node-positive breast cancer
Long-term follow-up data from multicenter phase III non-inferiority trials confirmed the safety of omission of axillary dissection in selected patients with clinically node-negative, sentinel node-positive breast cancer. Several ongoing trials investigate extended eligibility of the Z0011 protocol i...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-03-01
|
| Series: | Breast |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S0960977621004471 |
| _version_ | 1818278014460362752 |
|---|---|
| author | Nadia Maggi Rahel Nussbaumer Liezl Holzer Walter P. Weber |
| author_facet | Nadia Maggi Rahel Nussbaumer Liezl Holzer Walter P. Weber |
| author_sort | Nadia Maggi |
| collection | DOAJ |
| description | Long-term follow-up data from multicenter phase III non-inferiority trials confirmed the safety of omission of axillary dissection in selected patients with clinically node-negative, sentinel node-positive breast cancer. Several ongoing trials investigate extended eligibility of the Z0011 protocol in the adjuvant setting. De-escalation of axillary surgery in patients with clinically node-positive breast cancer is currently limited to the neoadjuvant setting, where the sentinel procedure is used to determine nodal pathological complete response. Targeted axillary dissection lowers the false-negative rate of the sentinel procedure, which, however, is consistently associated with a very low risk of axillary recurrence in several recent single-center series. Axillary dissection remains standard care in patients with residual disease after neoadjuvant chemotherapy while the results of Alliance A011202 are pending. The TAXIS trial investigates the role of tailored axillary surgery in patients with clinically node-positive breast cancer, a novel concept designed to selectively remove positive nodes in the adjuvant and neoadjuvant setting. |
| first_indexed | 2024-12-12T23:10:42Z |
| format | Article |
| id | doaj.art-e32b24786568454599d258461f698b72 |
| institution | Directory Open Access Journal |
| issn | 1532-3080 |
| language | English |
| last_indexed | 2024-12-12T23:10:42Z |
| publishDate | 2022-03-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Breast |
| spelling | doaj.art-e32b24786568454599d258461f698b722022-12-22T00:08:35ZengElsevierBreast1532-30802022-03-0162S50S53Axillary surgery in node-positive breast cancerNadia Maggi0Rahel Nussbaumer1Liezl Holzer2Walter P. Weber3Breast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, SwitzerlandBreast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, SwitzerlandDepartment of Gynecology, University Hospital Zurich, Zurich, SwitzerlandBreast Center, University Hospital Basel, Basel, Switzerland; University of Basel, Basel, Switzerland; Corresponding author. Breast Center, University Hospital Basel, Spitalstrasse 21, CH-4031, Basel, Switzerland.Long-term follow-up data from multicenter phase III non-inferiority trials confirmed the safety of omission of axillary dissection in selected patients with clinically node-negative, sentinel node-positive breast cancer. Several ongoing trials investigate extended eligibility of the Z0011 protocol in the adjuvant setting. De-escalation of axillary surgery in patients with clinically node-positive breast cancer is currently limited to the neoadjuvant setting, where the sentinel procedure is used to determine nodal pathological complete response. Targeted axillary dissection lowers the false-negative rate of the sentinel procedure, which, however, is consistently associated with a very low risk of axillary recurrence in several recent single-center series. Axillary dissection remains standard care in patients with residual disease after neoadjuvant chemotherapy while the results of Alliance A011202 are pending. The TAXIS trial investigates the role of tailored axillary surgery in patients with clinically node-positive breast cancer, a novel concept designed to selectively remove positive nodes in the adjuvant and neoadjuvant setting.http://www.sciencedirect.com/science/article/pii/S0960977621004471Breast cancerBreast surgeryAxillary dissectionSentinel lymph node procedureAxillary staging |
| spellingShingle | Nadia Maggi Rahel Nussbaumer Liezl Holzer Walter P. Weber Axillary surgery in node-positive breast cancer Breast Breast cancer Breast surgery Axillary dissection Sentinel lymph node procedure Axillary staging |
| title | Axillary surgery in node-positive breast cancer |
| title_full | Axillary surgery in node-positive breast cancer |
| title_fullStr | Axillary surgery in node-positive breast cancer |
| title_full_unstemmed | Axillary surgery in node-positive breast cancer |
| title_short | Axillary surgery in node-positive breast cancer |
| title_sort | axillary surgery in node positive breast cancer |
| topic | Breast cancer Breast surgery Axillary dissection Sentinel lymph node procedure Axillary staging |
| url | http://www.sciencedirect.com/science/article/pii/S0960977621004471 |
| work_keys_str_mv | AT nadiamaggi axillarysurgeryinnodepositivebreastcancer AT rahelnussbaumer axillarysurgeryinnodepositivebreastcancer AT liezlholzer axillarysurgeryinnodepositivebreastcancer AT walterpweber axillarysurgeryinnodepositivebreastcancer |